Skip to navigation Skip to content



About this Medication
  • Brand Name: Ocrevus® (oak-rev-us)
  • Chemical Name: ocrelizumab (ok-re-LIZ-ue-mab)
  • Usage in MS: Disease-Modifying Agent
  • Generic Available: No

This medication is taken by intravenous (IV) infusion.


Ocrevus® is a humanized monoclonal antibody that targets CD20 positive B lymphocytes ( a type of white blood cell), which contribute to nerve damage in MS. 

Ocrevus is approved by the FDA for the treatment relapsing forms of multiple sclerosis in adults, which include clinically isolated syndrome, relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS with relapses). Ocrevus is also approved by the FDA to treat primary progressive MS in adults.

Click to read the Prescribing Information for healthcare professionals.
Click to read the Medication Guide for patients.



Financial Assistance Program

Genentech® Access Solutions

Infusion Center Resources

National Infusion Center Association - non-profit patient advocacy organization which offers an online Infusion Center Finder to locate centers throughout the U.S. that administer IV/injectable medications. NICA also provides online consumer education to help patients learn more about infusion services.

What You Need to Know About Ocrevus™

This video was created in Summer 2017 and features Derrick Robertson, MD, Janice Maldonado, MD and Kathleen Costello, MSCN. Information is accurate as of then. To learn more about Ocrevus™ and other disease modifying therapy options, download the Consensus on Disease-Modifying Therapies.


© 2023 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.